Related Experiment Video
Updated: Jun 19, 2026
13:08
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
[Antitumor activity of zoledronic acid]
1Semmelweis Egyetem, Pulmonológiai Klinika, Budapest. tamasi@sterlingconsulting.org
Magyar Onkologia
|October 2, 2009
Summary
Amino-bisphosphonates like zoledronic acid show direct antitumor activity in bone metastases. Further clinical trials are necessary to confirm the real-world efficacy of these agents.
Area of Science:
- Oncology
- Pharmacology
Background:
- Bisphosphonates are crucial for managing bone metastases in cancer patients.
- Increased patient survival due to advanced therapies leads to a higher incidence of bone metastases.
Purpose of the Study:
- To review the direct antitumor effects of the amino-bisphosphonate zoledronate.
- To summarize in vitro and animal model data on zoledronic acid's anticancer properties.
Main Methods:
- Review of in vitro studies.
- Analysis of animal model research.
- Compilation of existing clinical data on zoledronic acid in solid tumors with bone metastases.
Main Results:
- Zoledronic acid demonstrates antitumor activity in preclinical studies.
- Clinical data suggests zoledronic acid prolongs survival in patients with bone metastases.
- Multiple pathomechanical pathways contribute to zoledronic acid's direct antitumor effects.
Conclusions:
- Zoledronic acid exhibits promising direct antitumor activity against bone metastases.
- Amino-bisphosphonates may offer significant clinical benefits beyond supportive care.
- Randomized clinical trials are essential to validate the antitumor efficacy of amino-bisphosphonates in real-world settings.
